Skip to main content
. 2022 Sep 23;13:904314. doi: 10.3389/fphar.2022.904314

FIGURE 7.

FIGURE 7

A scheme of the proposed mechanisms. Sorafenib treatment increases ATF3 expression by repressing Slc7a11 expression to suppress system Xc-in cardiomyocytes, and thereby predispose cells to a state prone to ferroptosis.